Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Pranlukast

Pranlukast

pharmaceutical raw materials
Pranlukast structure

Pranlukast 

structure
  • CAS No:

    103177-37-3

  • Formula:

    C27H23N5O4

  • Chemical Name:

    Pranlukast

  • Synonyms:

    Benzamide,N-[4-oxo-2-(2H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)-;Benzamide,N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)-;N-[4-Oxo-2-(2H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide;RS 411;ONO 1078;Pranlukast;ONO-RS 411;SB 205312;8-[4-(4-Phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran;Onon;CCN 00401;Azlaire;4-Oxo-8-[4-(4-phenylbutoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran

  • Categories:

    Active Pharmaceutical Ingredients  >  Respiratory Drugs

Description

Off-white solidPranlukast, a novel chromone derivative, was introduced in Japan for the treatment of bronchial asthma and allergic diseases. Pranlukast is a highly potent, selective and competitive antagonist of peptidoleukotrienes with high affinity for the LTD4 receptor. The therapeutic potential of pranlukast in managing irritable bowel syndrome has been suggested. Pranlukast is a common respiratory drug, it belongs to asthma drugs.


N-[4-oxo-2-(2H-tetrazol-5-yl)-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide is a member of chromones.|Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Pranlukast Basic Attributes

481.5

481.50

201-616-4

TB8Z891092

DTXSID9021180|DTXSID3043782

R - Respiratory system

Characteristics

119

4.2

off-white solid

1.374±0.06 g/cm3(Predicted)

236-238°C

1.681

Store at +4°C

LD50 in male mice (mg/kg): >1000 i.v. (Toda)

Safety Information

11-34

16-26-36/37/39-45

CV5647500

F,C

P264, P280, P302+P352, P305+P351+P338, P321, P332+P313, P337+P313, P362

H315

|Warning|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P273, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 40 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]|P264, P280, P302+P352, P305+P351+P338, P321, P332+P313, P337+P313, and P362|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Toxicity

Side effects include headache, abdominal or stomach pain, cough, dental pain, dizziness, fever, heartburn, skin rash, stuffy nose, weakness or unusual tiredness.

Drug Information

Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist.

A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)|Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)

Hepatic

Pranlukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Pranlukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.

8-(4 (4-phenylbutoxy)benzoyl)amino-2-(tetrazol-5'-yl)-4-oxo-4H-1-benzopyran

Pranlukast Use and Manufacturing

Labeled Pranlukast, intended for use as an internal standard for the quantification of Pranlukast by GC- or LC-mass spectrometry.Premastast is a commonly used respiratory medicine, belongs to antiasthmatic drugs, is a cysteine leukotriene (LTs) receptor antagonist, and selectively binds with LTC4, LTD4, LTE4 receptors to antagonize its effect .

Computed Properties

Molecular Weight:481.5
XLogP3:4.2
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:9
Exact Mass:481.17500423
Monoisotopic Mass:481.17500423
Topological Polar Surface Area:119
Heavy Atom Count:36
Complexity:778
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Unspecified

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • Cheer Fine Pharmaceutical Co., Ltd.

    Japan Japan
    Active
  • Beijing Fuweisi Biotechnology Co., Ltd.

    China China
    Active
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.

    China China
    Active

Recommended Suppliers of Pranlukast

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.